EU issues warning about HAART regimen.
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D016049:Didanosine / Q000009:adverse effects; D015224:Dideoxynucleosides / Q000009:adverse effects; D024882:Drug Resistance, Viral; D005062:European Union; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects; D018579:Patient Selection; D010865:Pilot Projects; D012449:Safety; D000068698:Tenofovir; D017211:Treatment Failure; D019562:Viral Load; D000099227:Abacavir
D000225:Adenine; D019380:Anti-HIV Agents; D016049:Didanosine; D015224:Dideoxynucleosides; D019259:Lamivudine; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D000068698:Tenofovir; D000099227:Abacavir